IMR Press / EJGO / Volume 9 / Issue 2 / pii/1988024

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research

Advanced uterine sarcoma; response to chemotherapy

Show Less
1 Chief, Department of Gynecologic Oncology -Professor of Gynecology, Dept. of Gynecologic Oncology, Roswell Park Memorial Institute - Buffalo, New York, USA
2 Fellow, Department of Gynecologic Oncology, Dept. of Gynecologic Oncology, Roswell Park Memorial Institute - Buffalo, New York, USA
Eur. J. Gynaecol. Oncol. 1988, 9(2), 124–129;
Published: 10 April 1988
Abstract

A 15 year retrospective study of chemotherapy response to multiple regimens em­ployed in 78 evaluable patients with advanced uterine sarcoma was performed. Single agent acti­vity was noted with doxorubicin, methotrexate, and cisplatin (5-11 % response rate). Effective multigent regimens included cyclosphosphamide, vincristine, doxorubicin, dacarbazine (CYV ADIC) (23% response), cisplatin, and dacarbazine (21 % response) and vincristine, dactinomycin, and cyclophosphamide (VAC) (18% response). There was no difference in response rate among di£­ferent histologies. More active agents or combinations are needed. 

Share
Back to top